医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega ViaFect™ Transfection Reagent Delivers High Performance Transfection Across Multiple Cell Lines, Including iPS Cells

2014年01月14日 PM11:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

ViaFect(TM) Transfection Reagent offers high performance transfection in a diversity of cell lines and iPSC-derived tissue cells. (Photo: Business Wire)ViaFect(TM) Transfection Reagent offers high performance transfection in a diversity of cell lines and iPSC-derived tissue cells. (Photo: Business Wire)

View and Share Photo

Close Window


MADISON, Wis.

Promega Corporation announces ViaFect™ Transfection Reagent, a tool for efficient DNA transfer into a wide variety of cell lines, including challenging suspension cells and stem cell-derived lines. ViaFect Transfection Reagent allows researchers to develop transfection-based assays in the cell line most relevant for their biology of interest.

ViaFect(TM) Transfection Reagent offers high performance transfection in a diversity of cell lines a ...

ViaFect(TM) Transfection Reagent offers high performance transfection in a diversity of cell lines and iPSC-derived tissue cells. (Photo: Business Wire)

Induced pluripotent stem cell (iPSC)-derived cell models, such as Cellular Dynamics International’s iCell® Cardiomyocytes, show robust transfection with ViaFect Transfection Reagent, enabling assays not possible with other reagents.

This low toxicity reagent allows cells to stay healthy and metabolically active during transfection-based experiments, even at low cell densities, facilitating experiments where extended application of a treatment is needed. Cell viabilities of greater than 90% are routinely observed following transfection with ViaFect Transfection Reagent.

ViaFect Transfection Reagent requires minimal optimization with a simple three-step protocol. It does not require removal of serum, removal of culture medium or washing after introduction of the reagent/DNA complex. ViaFect Transfection Reagent contains no animal-derived components. For more information or to sample the new reagent, see: www.promega.com/ViaFect. A poster detailing results using ViaFect Transfection Reagent will also be presented at the Society for Laboratory Automation and Screening Conference and Exhibition to be held January 18th-22nd in San Diego, CA.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140114005313/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent